文献速递骨软组织肉瘤与黑色素瘤支持与姑息治疗

儿童与青少年间皮瘤:EXPeRT协作组回顾性研究

Mesothelioma in children and adolescents: the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) contribution.
PubMed 文献 · Eur J Cancer · 2020-10-10

中位随访6.7年,5年总生存率82.3%(95%CI 67.8–99.9),5年无事件生存率45.1%(95%CI 28.4–71.7);顺铂-培美曲塞方案缓解率50%(6/12例),CRS-HIPEC可用于复发挽救。

要点

  • 儿童间皮瘤罕见,以腹膜原发为主,石棉暴露少见,结局优于成人。
  • 顺铂-培美曲塞一线缓解率50%(6/12例)。
  • CRS-HIPEC可用于初治、新辅助后或肿瘤进展后的挽救治疗。

核心结论

  • 儿童与青少年间皮瘤罕见,与成人不同:石棉暴露少、腹膜原发多、结局更好。
  • 顺铂-培美曲塞方案显示出有希望的疗效,复发可经含CRS-HIPEC的积极治疗挽救。

研究设计与样本

  • EXPeRT协作组回顾性分析1987–2018年诊断并治疗的≤21岁儿童、青少年及年轻成人间皮瘤患者。

主要发现

  • 原发肿瘤主要位于腹膜(23例);组织学为腹膜多囊性间皮瘤(MCM)6例、恶性间皮瘤(MM)27例。
  • MM一线治疗包括术前化疗14例、仅手术3例、仅化疗5例、辅助化疗3例、姑息治疗2例。
  • 顺铂-培美曲塞缓解率为50%(6/12例)。
  • CRS-HIPEC共19例: upfront 3例、新辅助治疗后12例、肿瘤进展后6例(其中3例两次)。
  • 中位随访6.7年(范围0–20年),5年总生存率82.3%(95%CI 67.8–99.9),5年无事件生存率45.1%(95%CI 28.4–71.7)。

临床怎么用

  • 儿童间皮瘤应结合腹膜原发多见、石棉暴露少的特点进行个体化评估。
  • 顺铂-培美曲塞可作为全身治疗选择,CRS-HIPEC可用于初治、新辅助后或进展后的挽救治疗。

局限性

  • 石棉暴露信息仅1例记录,暴露评估可能不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Very little is known about the characteristics of mesothelial tumours in the paediatric population. In adults with malignant mesothelioma, the pemetrexed-based regimen with cytoreductive surgery (CRS) is a standard of care in limited tumours, but long-term survival is uncommon. MATERIAL AND METHODS: The European Cooperative Study Group on Pediatric Rare Tumors (EXPeRT) retrospectively reviewed children, adolescents and young adults (≤21 year) diagnosed with mesothelial tumours treated between 1987 and 2018. RESULTS: Thirty-three patients were identified, 15 male and 18 female patients. One patient's exposure to asbestos was documented. Primary tumour was mainly in the peritoneum (23 patients). Histology was multicystic mesothelioma of the peritoneum (MCM) (six patients) or malignant mesothelioma (MM) (27 patients). Among MM, the first-line treatment comprised preoperative chemotherapy (14 cases), surgery only (three cases), chemotherapy only (five cases), adjuvant chemotherapy (three cases) or palliative treatment (two cases). The response rate to cisplatin-pemetrexed was 50% (6/12 cases). CRS with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) was performed in 19 patients (upfront in three, after neoadjuvant therapy in 12, or after tumour progression in six patients, including three twice). After a median follow-up of 6.7 years (range, 0-20), five-year overall and event-free survivals were 82.3% (95% CI, confidential interval ((CI), 67.8-99.9) and 45.1% (95% CI, 28.4-71.7), respectively. All patients with MCM are alive after surgery (five patients) and CRS-HIPEC (one patient). CONCLUSIONS: Paediatric mesothelioma is exceptional and seems to be different from its adult counterpart with few asbestos exposures, more peritoneal primary, and a better outcome. The cisplatin-pemetrexed regimen showed promising efficacy. Relapses could be salvaged with active therapy including CRS-HIPEC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Orbach D, André N, Brecht IB, et al. Mesothelioma in children and adolescents: the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT) contribution. Eur J Cancer. 2020. PMID: 33049597. doi:10.1016/j.ejca.2020.09.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。